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ABSTRACT
Objective: To determine the efficacy and safety of
etanercept and etanercept plus sulfasalazine versus
sulfasalazine in patients with rheumatoid arthritis (RA)
despite sulfasalazine therapy.
Methods: Patients were randomly assigned to etanercept
(25 mg twice weekly; sulfasalazine was discontinued at
baseline),etanerceptplussulfasalazine(unchangedregimen
of2–3 g/day)or sulfasalazineina double-blind,randomised,
2-year study in adult patients with active RA despite
sulfasalazine therapy. Efficacy was assessed using the
American College of Rheumatology criteria, disease activity
scores (DAS) and patient-reported outcomes (PRO).
Results: Demographic variables and baseline disease
characteristics were comparable among treatment groups;
mean DAS 5.1, 5.2 and 5.1 for etanercept (n = 103),
etanercept plus sulfasalazine (n = 101) and sulfasalazine
(n = 50), respectively. Withdrawal due to lack of efficacy
was highest with sulfasalazine (26 (52%) vs 6 (6%) for
either etanercept group, p,0.001). Patients receiving
etanerceptoretanerceptplussulfasalazinehadamorerapid
initial response, which wassustained at 2 years, than those
receiving sulfasalazine: mean DAS 2.8, 2.5 versus 4.5,
respectively (p,0.05); ACR 20 response was achieved by
67%, 77% versus 34% of patients, respectively (p,0.01)
Overall,PROfollowedasimilarpattern;aclinicallysignificant
improvement in health assessment questionnaire was
achieved by 76%, 78% versus 40% of patients, respectively
(p,0.01). Commonly reported adverse events occurring in
the etanercept groups were injection site reactions and
pharyngitis/laryngitis (p,0.01).
Conclusion: Etanercept and etanercept plus sulfasalazine
are efficacious for the long-term management of patients
with RA. The addition of etanercept or substitution with
etanercept should be considered as treatment options for
patients not adequately responding to sulfasalazine.
Several options including disease-modifying anti-
rheumatic drugs (DMARD), such as methotrexate
and sulfasalazine and anti-tumour necrosis factor
(TNF) agents such as etanercept, infliximab and
adalimumab, are available for the treatment of
patients with rheumatoid arthritis (RA). For
patients with an inadequate response to DMARD
therapy, one recommended therapeutic option is
anti-TNF therapy either added to or as a replace-
ment for the existing regimen.
12
In clinical studies, anti-TNF agents are highly
effective and generally well tolerated when added to
existing treatment regimens for patients with active
RA who do not respond to a DMARD such as
methotrexate
3–8 or sulfasalazine, another frequently
prescribed DMARD. However, there are very few
studies assessing the benefits and risks of adding an
anti-TNF agent to existing sulfasalazine therapy for
patients with RA inadequately responding to
sulfasalazine.
9–12 Combe et al
10 previously reported
on the 6-month interim results from the current
study; the 6-month results showed that etanercept,
in combination with or in place of sulfasalazine,
resulted in substantial improvements in RA.
10 Both
etanercept regimens were well tolerated.
10
This 2-year report provides data on the long-
term therapeutic response including patient-
reported outcomes (PRO) and safety of etanercept,
added to or in place of sulfasalazine, versus
sulfasalazine alone in patients with active RA,
despite stable sulfasalazine therapy.
PATIENTS AND METHODS
Study design and patients
This was a 2-year randomised, double-blind, double-
dummy, multicentre study in patients with active
RA who had an inadequate response to sulfasalazine.
Eligible patients were 18 years of age or older with
disease duration of 20 years or less with active adult-
onset RA (functional class I–III), defined as six or
more swollen and 10 or more tender joints and one
or more of the following: erythrocyte sedimentation
rate (ESR; Westergren) >28 mm at the end of the
first hour; serum C-reactive protein >20 mg/l and
morning stiffness for 45 minutes or longer. Patients
must have received stable doses of sulfasalazine (2–
3 g daily) for 4 months or more before screening.
Details of the exclusion/inclusion criteria have been
published previously.
10
This study was conducted in accordance with
the International Conference on Harmonisation
guidelines for good clinical practice in the European
Community and the Declaration of Helsinki.
Ethics committees of the participating centres
approved the study protocol. Patients gave written
informed consent before participating in the study.
Treatment
Patients were randomly assigned to one of three
treatment groups (in a 2 : 1 : 2 ratio): etanercept
(etanercept 25 mg by subcutaneous injection twice
Extended report
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daily plus placebo) or combination (etanercept plus sulfasala-
zine) therapy. Patients in the etanercept group discontinued
sulfasalazine at baseline.
Clinical assessment
Response to therapy was assessed at baseline and at weeks 2, 4, 8,
12,16,20,24,32,40,48,56,68,80,92and104.Theprimaryefficacy
endpoint, the percentage of patients achieving 20% or greater
improvement, as defined by American College of Rheumatology
(ACR) 20 criteria,
13 at week 24, was reported previously.
Key efficacy assessments included ACR response rates (ACR
20, ACR 50 and ACR 70), disease activity score (DAS) and
morning stiffness in minutes. Assessments were based on ACR
criteria and DAS as previously reported.
10
PRO measures included the health assessment questionnaire
(HAQ) disability index,
14 15 EQ-5D visual analogue scale (VAS),
16
patient global assessment of overall RA activity (PGAD) and
patient general health assessment (GHVAS). The PGAD is
recorded on an 11-point numeric rating scale in which a score of
zero means no disease activity and a score of 10 means extreme
disease activity. For the GHVAS, patients responded to the
question ‘‘How do you feel concerning your arthritis?’’ by
marking the appropriate position on a 100-mm VAS ranging
from ‘‘very well’’ to ‘‘extremely bad.’’ For both PGAD and
GHVAS, lower scores imply better health.
To determine whether PRO closely reflected clinical improve-
ments, the study examined the relationship between changes in
health status measures or disability and changes in disease
activity. Pearson correlation analysis was performed between
the four PRO measures (HAQ, EQ-5D VAS, PGAD and
GHVAS) and a measure of disease activity, DAS.
Safety assessments
Safety assessments were based on reports of adverse events and
results of routine physical examinations and laboratory determi-
nations. An event was considered to be a treatment-emergent
adverse event (TEAE) if it occurred during the study or if the
severity or frequency of a preexisting event increased during the
study. A serious adverse event (SAE) included any event resulting
in death, hospitalisation or cancer. An infection was a serious
infection if reported as an SAE.
Testing for antinuclear, anti-double-stranded DNA, anti-
etanercept and anti-cardiolipin antibodies was performed at
screening and at specified visits.
The incidence of malignancies in this study was compared with
the incidence estimated from the US National Cancer Institute’s
(NCI) surveillance, epidemiology, and end results (SEER) data-
base.
17 The age and sex-specific incidence rates for cancer from the
SEER database were applied to the exposure in this study.
Statistical analysis
The ACR 20, ACR 50 and ACR 70 response rates were analysed
using the Mantel–Haenszel x
2 test, stratified by study centre.
Changes from baseline in components of the ACR and PRO
(HAQ disability index, EQ-5D, GHVAS and PGAD) were
analysed with a two-way analysis of covariance with treat-
ments and centre as factors and the baseline as a covariate.
Efficacy analyses were based on a modified intent-to-treat
population, including patients who received any test article and
provided efficacy data at baseline and at any subsequent visit.
The proportions of patients with clinically meaningful changes
in the HAQ disability index at week 104 were compared
between treatment groups using x
2 analyses. Pearson correlation
analyses were used to assess correlations between DAS and PRO
over 104 weeks. The last-observation-carried-forward (LOCF)
approach was used to account for missing data points. LOCF
imputation was also applied to patients who discontinued for
unsatisfactory response. Adverse events were summarised and
compared among treatment groups, using x
2 or Fisher’s exact
test. The sample sizes, 100 for the etanercept-alone group and
sulfasalazine plus etanercept group versus 50 for the sulfasala-
zine-alone group, gave approximately 90% power to detect
pairwise differences in the ACR 20 response of 33% versus 66%
between the monotherapies.
RESULTS
Efficacy
Of the 260 patients who were randomly assigned in the study,
254 patients received one or more test articles (etanercept 103,
Figure 1 Percentage of patients remaining in the study versus time (in
weeks). Based on the log-rank test, the p values for the comparisons of
the time to discontinuation are ,0.001 (sulfasalazine versus etanercept),
,0.001 (sulfasalazine versus combination), and 0.06 (etanercept versus
combination).
Figure 2 Mean disease activity score (DAS) over time (in weeks;
last-observation-carried-forward, modified intent-to-treat analysis).
, Etanercept plus sulfasalazine; $ etanercept; & sulfasalazine.
*p,0.05 etanercept versus combination;
{p,0.05 sulfasalazine versus
combination;
{p,0.05 sulfasalazine versus etanercept.
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10 The population was
predominantly white, female, and had a mean age of 51 years
(consistent with the typical RA population). As previously
reported, there were no significant differences among the groups
in the baseline characteristics with the exception of the
percentage of patients receiving previous corticosteroids and
the mean number of previous DMARD.
10
A total of 96 patients discontinued the study: 38 receiving
etanercept, 34 receiving sulfasalazine and 24 receiving combina-
tion therapy. Overall, a significantly greater number of the
patients who continued on sulfasalazine monotherapy (68%)
withdrew from the study compared with those receiving
etanercept, either as combination (24%) or replacement (37%)
therapy (p,0.001); the difference between etanercept and the
combination was also significant (p,0.05). The most common
primary reason for discontinuation, lack of efficacy, led to a
significantly higher number of withdrawals in patients receiving
sulfasalazine (52%) compared with those receiving either
etanercept regimen (6% for each; p,0.001). Discontinuations
because of adverse events were not significantly different
among the groups (8%, 19% and 10%, for the sulfasalazine,
etanercept and combination groups, respectively) and there was
no trend in the types of adverse events that led to discontinua-
tion in any of the groups.
Times to discontinuation were estimated using the Kaplan–
Meier method (fig 1); the combination group had the longest
times to discontinuation. Based on the log-rank test, the
differences among the three groups were statistically significant
(p,0.001 for sulfasalazine vs etanercept or combination and
p=0.06 for etanercept vs the combination).
Disease activity, as assessed by mean DAS, was significantly
lower in the groups receiving etanercept than in the group
receiving sulfasalazine from week 2 to week 104 (p,0.01, fig 2).
Significantly lower mean DAS values were observed during weeks
68–104 for the combination group compared with the etanercept-
alone group (p,0.05). A significantly higher proportion of patients
receiving the combination or etanercept had a low level of disease
activity (as assessed by DAS ,2.4) compared with those receiving
sulfasalazine after 6 months, which was maintained throughout
the 2 years (p,0.01); at 2 years, 57.0% of patients receiving
combination, 45.6% receiving etanercept and 4.0% receiving
sulfasalazine. Likewise, the proportion of patients achieving
Figure 3 Percentage of patients in each treatment group achieving an
American College of Rheumatology (ACR) response (last-observation-
carried-forward). (A) ACR 20; (B) ACR 50 and (C) ACR 70. , Etanercept
plus sulfasalazine; $ etanercept; & sulfasalazine.
*p,0.01 etanercept
versus combination;
{p,0.01 sulfasalazine versus combination;
{p,0.05
sulfasalazine versus etanercept.
Figure 4 Mean health assessment questionnaire (HAQ) scores from
baseline to week 104 for patients with rheumatoid arthritis receiving
sulfasalazine (SSZ), etanercept (ETN), or combination therapy with
sulfasalazine and etanercept (last-observation-carried-forward analysis).
, Etanercept plus sulfasalazine; $ etanercept; & sulfasalazine.
*p,0.01 sulfasalazine versus etanercept;
{p,0.01 sulfasalazine versus
combination.
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groups compared with the sulfasalazine group (p,0.01).
Treatment response as assessed by ACR 20 was achieved by a
significantly higher percentage of patients receiving etanercept,
added to or in place of sulfasalazine, compared with those
receiving sulfasalazine (p,0.01; fig 3A). Similarly, these
significant differences in treatment response among the groups
were also seen using ACR 50 (p,0.01) and ACR 70 (p,0.01;
fig 3B,C) criteria. For ACR 20 responses, the differences were
significant beginning at week 2; for ACR 50 and ACR 70, the
differences were significant beginning at weeks 8 and 12,
respectively. Response rates were not significantly different
between the two groups receiving etanercept.
The early and sustained response pattern was also seen with
components of the ACR response criteria. Significant differences
(p,0.01) were seen for combination therapy or etanercept alone
compared with sulfasalazine alone. Comparing the etanercept
groups, the combination group separated from the etanercept
monotherapy group for a short period (weeks 8 to 20) as
demonstrated by the lower ESR levels (p,0.05). No significant
difference between these groups was seen for other ACR
components before week 68 (total swollen joints) or week 92
(patient global assessment and physician global assessment),
after which time the combination group showed better
responses (p,0.05).
Patient-reported outcomes
Mean HAQ values for the etanercept and combination groups
were significantly lower than those for the sulfasalazine group
from week 2 (p,0.01, sulfasalazine vs etanercept or combina-
tion) and these differences were sustained for the remainder of
the 2-year study
10 (p,0.01; fig 4).
Three health status measures using least squares means at
week 104 are presented in fig 5. Patients who received
etanercept or combination therapy showed significantly lower
GHVAS scores, indicative of better general health, than patients
who received sulfasalazine at week 104. Likewise, recipients of
etanercept or combination therapy reported significantly better
health states, as indicated by lower RA activity (PGAD) and
higher EQ-5D scores than patients receiving sulfasalazine.
Our analyses also found that a significantly higher proportion
of patients receiving etanercept or the combination attained the
threshold of HAQ improvement >0.22 by week 104 compared
with those receiving sulfasalazine (p,0.01 compared with
sulfasalazine alone). Similarly, a significantly higher proportion
of patients receiving etanercept or the combination achieved
EQ-5D VAS scores above population norms
18 at week 104
compared with those receiving sulfasalazine (p,0.01 compared
with sulfasalazine alone).
Further analyses revealed that changes in disease activity
from baseline to 104 weeks correlated with changes in disability
as measured by the HAQ disability index and with changes in
health status measures. Pearson correlations between the
change from baseline in DAS and HAQ (0.57), PGAD (0.69),
EQ-5D VAS (20.61), or GHVAS (0.67) were all significant
(p,0.001).
Safety
The pattern of adverse events reported during the 2 years of the
study was not different from that reported during the first
6 months of the study.
10 There were no significant differences
between the combination and either monotherapy groups in the
overall incidence of non-infectious adverse events (table 1).
However, there were significantly more treatment-emergent
infections in patients receiving etanercept than in those
receiving sulfasalazine (p,0.001).
Treatment-emergent infections per patient-year were signifi-
cantly higher with etanercept (1.72) than with etanercept and
sulfasalazine (1.11) or with sulfasalazine (0.86; p,0.001 over-
all). There were significant differences between the etanercept
group and both the sulfasalazine and combination groups
(p,0.001). Medically important infections occurred in more
patients receiving etanercept (11; 10.7%) than in those receiving
combination (5; 5%, p not significant) or sulfasalazine (0;
p,0.05). After 352 days receiving combination therapy, one
patient was hospitalised and withdrawn from the study and
Figure 5 Health status at baseline and week 104 for patients with
rheumatoid arthritis receiving etanercept, sulfasalazine, or combination
therapy as measured by least squares means for EQ-5D, patient general
health assessment (GHVAS) and global assessment of overall
rheumatoid arthritis activity (PGAD) (last-observation-carried-forward
analysis). (A) EQ-5D; (B) GHVAS; (C) PGAD.
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determination of tuberculous lymphadenitis.
There was no clustering of SAE. In the 2 years of the study,
23 patients receiving the combination, 27 receiving etanercept
and two receiving sulfasalazine had one or more SAE. Non-
infectious SAE were significantly greater in patients receiving
etanercept (20.8% for the combination and 20.4% for etanercept
alone) compared with 4% for patients receiving sulfasalazine
(p,0.01).
At all scheduled visits, patients receiving the combination had
a significantly greater reduction in white blood cell (WBC)
counts (mean change from baseline) than those receiving
sulfasalazine alone (p,0.001). In contrast, there was no
significant difference in this laboratory parameter between the
etanercept and sulfasalazine groups. Across all treatment
groups, no subjects developed any NCI grade 3 or 4 WBC
abnormalities, except for one subject who had a transient grade
4 WBC abnormality that normalised. All mean WBC counts
were within normal limits at all visits.
Leucopenia was reported as a TEAE in eight (7.9%) patients in
the combination group, two (1.9%) in the etanercept group and
none in the sulfasalazine group (p not significant). None of the
events of leucopenia were associated with NCI grade 3 or 4
levels of neutrophils or other NCI grade 3 or 4 laboratory
abnormalities. No patients withdrew from the study because of
TEAE of leucopenia; all events were resolved during the study.
Malignancy was diagnosed in two patients receiving etaner-
cept. One patient with a history of skin cancer developed actinic
squamous cell carcinoma of the lower lip. The second patient,
whose diagnosis was myelodysplastic syndrome after 12 weeks
of etanercept, then developed myelocytic leukaemia and
subsequently died.
The incidence of malignancy observed in this study was
compared with the expected incidence based on the US SEER
programme. The observed number (1.0) of malignancies in
etanercept or combination-treated patients during the entire
study was lower than the expected numbers (2.7) based on
SEER, which excludes non-melanoma skin cancers.
17
The second reported death was a patient with interstitial
pneumonitis, who had a history of smoking, coronary obstruc-
tive pulmonary disease and childhood pneumonia.
No patients developed systemic lupus erythematosus or a
lupus-like syndrome, glomerulonephritis, pleuritis, peritonitis, or
seizure.There werenoreports of centraldemyelinating diseasesin
this study. Occurrences of auto-antibodies were not significantly
different among groups at baseline and at the last visit.
DISCUSSION
The results from this 2-year double-blind, randomised study in
patients with active RA despite sulfasalazine therapy provide
further evidence that etanercept, either alone or when added to
existing DMARD therapy, has a favourable long-term safety
and efficacy profile. The addition of or switching to etanercept
resulted in a rapid and sustained improvement of all clinical
efficacy endpoints compared with sulfasalazine alone. The
efficacy results were similar in both etanercept groups,
indicating that patients inadequately responding to sulfasala-
zine would benefit by either the addition of etanercept to their
existing (sulfasalazine) treatment or by switching from sulfasa-
lazine to etanercept. Treatment with etanercept, sulfasalazine, or
Table 1 Number (%) of patients with the most common TEAE (>10% in any treatment group)
Body system TEAE
Etanercept
(n = 103)
Etanercept +
sulfasalazine
(n = 101)
Sulfasalazine
(n = 50)
Non-infectious adverse events
Any TEAE (excluding infection) 90 (87.4) 80 (79.2) 32 (64.0)*
Injection site reaction 34 (33.0) 21 (20.8) 2 (4.0)*{
Headache 11 (10.7) 25 (24.8){ 4 (8.0){
Back pain 9 (8.7) 20 (19.8) 5 (10.0)
Nausea 7 (6.8) 19 (18.8){ 5 (10.0)
Accidental injury 16 (15.5) 17 (16.8) 1 (2.0)*{
Asthenia 5 (4.9) 16 (15.8){ 1 (2.0){
Rash 15 (14.6) 8 (7.9) 3 (6.0)
Dyspepsia 14 (13.6) 12 (11.9) 2 (4.0)
Abdominal pain 14 (13.6) 12 (11.9) 1 (2.0)
Injection site haemorrhage 9 (8.7) 14 (13.9) 3 (6.0)
Arthralgia 8 (7.8) 14 (13.9) 7 (14.0)
Rheumatoid arthritis 10 (9.7) 12 (11.9) 5 (10.0)
Diarrhoea 11 (10.7) 6 (5.9) 0.0*
Cough increased 7 (6.8) 12 (11.9) 4 (8.0)
Parasthesia 4 (3.9) 11 (10.9) 1 (2.0)
Infectious adverse events
Any TEAE infection 76 (73.8) 60 (59.4){ 21 (42.0) *
Upper respiratory tract infection 29 (28.2) 29 (28.7) 10 (20.0)
Pharyngitis/laryngitis 24 (23.3) 10 (9.9) 3 (6.0)*{
Bronchitis 21 (20.4) 12 (11.9) 4 (8.0)
Flu syndrome 18 (17.5) 12 (11.9) 2 (4.0)
Gingival/dental infection 7 (6.8) 12 (11.9) 2 (4.0)
Sinusitis 12 (11.7) 3 (3.0){ 0.0*
Miscellaneous skin infections1 19 (18.4) 12 (11.9) 0.0*{
Fisher’s exact pairwise comparisons: *p,0.05 etanercept versus sulfasalazine; {p,0.05 etanercept versus combination and
{p,0.05 combination versus sulfasalazine. 1The types of skin infections included commonly reported events such as acne,
phlebitis, fungal infections and nail disorders. TEAE, treatment-emergent adverse event.
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The combination of etanercept and sulfasalazine was not
associated with greater toxicity than either therapy alone.
Modifications to a less than adequate treatment regimen,
such as the addition of another agent or substitution of a
‘‘failing’’ drug with another agent, are a standard approach.
Clinical studies in patients with RA have shown that adding or
substituting an anti-TNF agent to the existing methotrexate
therapy
3471 92 0 results in a significant improvement in the
therapeutic response. The addition of an anti-TNF agent to (or
in place of) inadequate sulfasalazine has not been extensively
evaluated in clinical trials. In the only other placebo-controlled
trial in RA patients not adequately treated with sulfasalazine,
adalimumab was added to the existing treatment.
91 2 . In that
study, patients receiving the combination showed a greater
degree of improvement than those receiving sulfasalazine alone.
However, modest sample sizes (sulfasalazine alone, n = 33;
sulfasalazine plus adalimumab, n = 29) make it difficult to
compare the efficacy results among the treatment arms. In a
larger open-label study evaluating adalimumab alone and in
patients inadequately responding to at least one traditional
DMARD, the number of ACR 20 responders was similar for
adalimumab plus sulfasalazine and adalimumab alone.
11
Patients who received etanercept monotherapy or etanercept
plus sulfasalazine combination achieved significantly higher
ACR response rates than patients in the sulfasalazine mono-
therapy group (p,0.01). For all three treatment groups, the core
components generally followed the pattern of the ACR
composite response. Mean ESR values in both the etanercept
plus sulfasalazine combination and etanercept monotherapy
groups were significantly lower than in the sulfasalazine
monotherapy group from week 2 (p,0.01) to week 104
(p,0.01). For a short period (week 8 to week 20) the
combination group had significantly lower ESR levels than the
etanercept-alone group (p,0.05), but the difference was not
significant from week 24 to week 104.
Physical function scores were significantly improved in the
groups receiving etanercept, either alone or in combination with
sulfasalazine, compared with sulfasalazine alone, using several
previously defined thresholds.
21 22 In patients with RA, a change
of 0.22 or more units in the HAQ score has been used to
estimate the number of patients with a clinically significant
improvement in physical function.
22 In this study, by week 104,
three in every four patients receiving etanercept, either alone or
as add-on therapy, achieved a HAQ improvement of 0.22 or
more, compared with less than 1 in two patients continuing on
sulfasalazine therapy.
Etanercept and combination therapy resulted in significantly
greater improvements in all measured PRO than the modest
improvements seen with sulfasalazine therapy. Furthermore,
there was a significant correlation between disease activity, as
assessed by the DAS, and physical function, as assessed by the
HAQ. Significant correlation was also observed between disease
activity and other PRO, including the EQ-5D VAS and PGAD.
The study was originally designed as a 6-month trial, which is
not long enough to detect radiographic changes, but was
subsequently extended to 2 years. However, because both
disease activity and radiographically assessed joint damage have
been shown to be major contributors to the physical function-
ing of the patient with RA,
23–26 the significant improvements in
disease activity and physical functioning would suggest that
radiographic progression was inhibited in these patients.
Treatment with etanercept, sulfasalazine, or the combination
did not result in any unexpected safety findings; however, the
comparison of TEAE among treatment groups in this study has
bias. Generally, with any drug patients report adverse events at
a higher frequency during the first few weeks or months after
the start of treatment and patients who cannot tolerate the
drug are withdrawn. As a protocol-inclusion criterion, patients
in the sulfasalazine group were required to have tolerated
sulfasalazine well; hence, these patients were expected to report
adverse events at a lower rate than patients receiving a ‘‘new’’
treatment.
The use of anti-TNF agents has also been associated with the
increased frequency of autoantibodies, which could result in
autoimmune diseases such as systemic lupus erythematosus.
27–29
Although the number of patients who tested positive for anti-
dsDNA increased by the end of our study, there were no
relevant clinical symptoms associated with the positive anti-
dsDNA test results in any of the treatment groups.
Leucopenia, neutropenia, thrombocytopenia and pancytope-
nia have also been reported in patients receiving anti-TNF
therapies. In this study, the incidence of TEAE of leucopenia
was greater in the combination group (7.9%) than in the
etanercept group (1.9%) or the sulfasalazine group (0%), but
between-group differences were not statistically significant.
Investigators categorised the severity of all eight events in the
combination group as mild; none of the TEAE of leucopenia
were associated with NCI grade 3 or 4 values of neutrophils or
with other NCI grade 3 or 4 laboratory abnormalities. No
patients withdrew from the study because of leucopenia. The
lower WBC counts thus did not seem to be clinically relevant.
Furthermore, there were no reports of aplastic anaemia or
pancytopenia.
This study shows that the addition of etanercept to
sulfasalazine, a DMARD other than methotrexate, can provide
significant long-term improvement in efficacy. In particular, it
shows that etanercept provides benefit when added to or
switched with sulfasalazine in patients who show an inade-
quate response to sulfasalazine. The reported findings are
especially relevant in view of the recent reports regarding
monotherapy failures, which discourage the choice of both
methotrexate plus sulfasalazine and leflunomide plus sulfasala-
zine combination therapy.
30 31 Generally, combination treat-
ment was not associated with an increased incidence of adverse
events. Etanercept either alone or added to existing sulfasalazine
therapy is associated with a favourable risk benefit profile, thus
broadening the range of options for the treatment of patients
with active RA.
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